On November 5, the 4th China International Import Expo was held at the National Convention and Exhibition Center (Shanghai) as scheduled. 58 countries and 3 international organizations participated in the national exhibition, and nearly 3,000 exhibitors from 127 countries and regions appeared at the enterprise exhibition.

On the afternoon of the 5th, Lan Foan, deputy secretary of the CPC Shanxi Provincial Committee and governor of Shanxi Province, came to the Shanghai National Convention and Exhibition Center to visit the exhibition hall, visit guests, carry out in-depth docking and promote Shanxi. Shanxi Jinbo Bio-pharmaceutical Co., Ltd., as a representative enterprise in the Shanxi bio-pharmaceutical field, appeared in the bio-pharmaceutical area of the Shanxi Provincial Exhibition Hall of the Fourth China International Import Expo (E3) with a number of "hard core" technology products, and won wide acclaim for its advanced technology and excellent efficacy.

Two "black technologies" from Jinbo Pharma garner fans with their strength

In recent years, Jinbo Pharma has always adhered to original innovation, based on the two major industrial fields of repair and regeneration and new biological materials against aging, and anti-virus functional protein, and has achieved the first industrialization of recombinant humanized type III collagen and anti-HPV-acid anhydride bovine β-lactoglobulin in the world, which has filled the international gap in their respective fields.

The products such as Ayouth, WFE MOR, Jinbo and Lanmi series presented in this exhibition are all from these two "black technologies".

Anti-HPV-acid anhydride bovine β-lactoglobulin

Anti-HPV-acid anhydride bovine β-lactoglobulin is a virus entry inhibitor, which can block high-risk HPV infection, reduce local viral load, and prevent cervical lesions. At present, it has won many patents and the silver award at the Geneva International Exhibition of Inventions.

A gel product containing anti-HPV-acid anhydride bovine β-lactoglobulin—Jinbo ® Anti-HPV biological protein dressing has solved the problem of HPV infection in many women and effectively reduced the incidence rate of cervical cancer in China.

Recombinant humanized type III collagen

The repeating unit of the amino acid sequence of recombinant humanized collagen type III is 100% the same as the specific functional region of the amino acid sequence of human collagen. It has a 164.88 ° flexible triple helix structure and high biological activity. Its relevant structural data have been included in the international protein structure database. This technology has broad application prospects in the fields of vascular endothelium, endometrium, wound, oral mucosa repair and orthopedics.

On June 29, this year, the world's first terminal landmark product, using a new biological material, humanized collagen, independently developed by Jinbo Pharma—" Lyophilized Fiber of Recombinant Humanized Type III Collagen " as Class III medical appliances for injection, was approved by NMPA for listing, laying a good foundation for clinical application and industrial transformation of related materials.

At the exhibition site, many exhibitors and customers stopped in front of the booth to inquire and negotiate cooperation. The relevant person in charge of Jinbo Pharma warmly received and introduced the technology principle of the recombinant humanized type III collagen and the anti-HPV-acid anhydride bovine β-lactoglobulin in detail, as well as the characteristics of each product. The visitors gave high recognition and evaluation to Jinbo Pharma’s "black technology" products.

Shanxi Jinbo Bio-pharmaceutical Co., Ltd

Shanxi Jinbo Bio-pharmaceutical Co., Ltd. is an excellent enterprise in Shanxi Province and a national high-tech enterprise. Founded in March 2008, the company has devoted itself to research and always adhered to original innovation for 14 years. With the application of international cutting-edge structural biology, protein engineering technology and biological fermentation engineering technology, based on the two major industrial fields of repair and regeneration and new biological materials against aging, and anti-virus functional protein, it has realized the first industrialization of recombinant humanized type III collagen and anti-HPV-acid anhydride bovine β-lactoglobulin in the world, which has filled the international gap in their respective fields. Moreover, the company is committed to becoming the leading enterprise of functional protein in China.